Daniel Evans
Sydney, New South Wales, Australia
13K followers
500+ connections
View mutual connections with Daniel
Daniel can introduce you to 10+ people at Southern Star Research
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Daniel
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Activity
13K followers
-
Daniel Evans shared thisI’m swapping the Sydney Winter 🥶 for the US Summer ☀️ However it will be less Santa Monica Beach and more: Conferences, Mammoth TSA queues and trying to cram in months worth of clothing into 1 suitcase. I’ll be travelling with Southern Star Research across Chicago, New Orleans, Salt Lake City, Phoenix, San Diego and settling for a few months in the global headquarters of Biotech: Cambridge / Boston, MA! Look forward to meeting US biotech leaders and clinical development teams to discuss how Australia and APAC can support smarter, faster and more efficient clinical development. I’ll also be attending American Society of Clinical Oncology (ASCO) in Chicago, American Diabetes Association Scientific Sessions in New Orleans and Austrade events. If you’re around, I’d love to connect: https://lnkd.in/gkABPivk #AustralianClinicalTrials #SouthernStarResearch #USRoadshow #ClinicalDevelopment #Biotech #ASCO #ADADaniel Evans shared thisDaniel Evans, 𝐃𝐢𝐫𝐞𝐜𝐭𝐨𝐫 𝐨𝐟 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭, 𝐢𝐬 𝐡𝐞𝐚𝐝𝐢𝐧𝐠 𝐬𝐭𝐚𝐭𝐞𝐬𝐢𝐝𝐞 𝐭𝐡𝐢𝐬 𝐬𝐮𝐦𝐦𝐞𝐫, 𝐚𝐧𝐝 𝐰𝐞’𝐝 𝐥𝐨𝐯𝐞 𝐭𝐨 𝐜𝐨𝐧𝐧𝐞𝐜𝐭. From Chicago to Boston, Daniel will be meeting with biotech and clinical development leaders across the US to discuss how Southern Star Research helps sponsors de-risk clinical trials and accelerate development through Australia and the broader APAC region. If you’re attending any of the events below, or based nearby, now’s the time to book a conversation. 📍 Chicago, IL (𝑨𝑺𝑪𝑶 2026) 🗓 May 29 – June 2, 2026 📍 New Orleans, LA (𝑨𝑫𝑨 𝑺𝒄𝒊𝒆𝒏𝒕𝒊𝒇𝒊𝒄 𝑺𝒆𝒔𝒔𝒊𝒐𝒏𝒔) 🗓 June 5 – 8, 2026 📍 Salt Lake City, UT 🗓 June 9 – 17, 2026 📣 Participating in the Australian Trade and Investment Commission (Austrade) event: Exploring New Models of Global Clinical Trial Collaboration on Wednesday, 𝐉𝐮𝐧𝐞 𝟏𝟕, 𝟐𝟎𝟐𝟔 𝐟𝐫𝐨𝐦 𝟏𝟐–𝟐𝐩𝐦 (𝐌𝐓) 📍 Phoenix, AZ 🗓 June 18 – 20, 2026 📣 Participating in the Australian Trade and Investment Commission (Austrade) event: Exploring New Models of Global Clinical Trial Collaboration on Thursday, 𝐉𝐮𝐧𝐞 𝟏𝟖, 𝟐𝟎𝟐𝟔 𝐟𝐫𝐨𝐦 𝟏𝟐–𝟐𝐩𝐦 (𝐌𝐓) 📍 San Diego, CA 🗓 June 22 – 27, 2026 📍 Boston, MA 🗓 June 27 – August 22, 2026 Whether you're exploring first-in-human studies, looking to streamline timelines, or evaluating APAC trial strategies, Daniel is available to discuss how Southern Star Research supports biotech teams with responsive, regionally informed clinical delivery. Book time with Daniel while he’s in your city- https://lnkd.in/gkABPivk #ClinicalTrials #Biotech #CRO #ClinicalResearch #APAC #DrugDevelopment #Biotechnology #EarlyPhaseTrials #ASCO2026 #ADAScientificSessions #SouthernStarResearch #USRoadshow
-
Daniel Evans reposted thisDaniel Evans reposted this𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐬 𝐭𝐚𝐤𝐞𝐬 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝐞𝐱𝐞𝐜𝐮𝐭𝐢𝐨𝐧. 𝐈𝐭 𝐭𝐚𝐤𝐞𝐬 𝐭𝐡𝐞 𝐫𝐢𝐠𝐡𝐭 𝐩𝐚𝐫𝐭𝐧𝐞𝐫. Southern Star Research will be attending 𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔 in Chicago from May 29 – June 2, 2026. Our CEO, Lloyd Prescott, and Director, Business Development, Daniel Evans will be onsite meeting biotech and medtech teams advancing oncology programs. At Southern Star Research, we support early-phase oncology trials with scientific insight, strong site relationships, and the speed advantages of Australia, with seamless expansion into APAC to enable multi-country studies without sacrificing speed or flexibility. If you are attending, we would be glad to connect. Book a meeting here: https://lnkd.in/gkABPivk #ASCO2026 #OncologyResearch #ClinicalTrials
-
Daniel Evans shared thisLooking forward to being back in Salt Lake City, UT and visiting Phoenix, AZ next month with Australian Trade and Investment Commission (Austrade) and peers from the industry for the "Exploring New Models of Global Clinical Trial Collaboration" Roadshow. Utah and Arizona are 2 of the fastest growing states in the US for biotech innovation and Life Sciences - many companies from both states engaging with Australia to take advantage of the many benefits on offer for companies performing Clinical Research. The 'Lunch & Learn' format will engage with local biotech companies and leaders from the Utah and Arizona ecosystems, including representatives from BioUtah, Economic Development Corporation of Utah (EDCUtah), Arizona BioIndustry Association (AZBio) and Phoenix Community and Economic Development - across the course of the events Australian capabilities across Clinical Trials will be presented, with help from leading CROs, Clinical Site, CDMO, Finance and Accounting as well as Bioanalytical and Pathology providers to showcase the turnkey Australian offering. Event Details: - Salt Lake City, UT - 17th June 2026 - 12:00 to 14:00 MT Register Here: https://lnkd.in/gY8s5tDj Phoenix, AZ - 18th June 2026 - 12:00 to 14:00 MT Register Here: https://lnkd.in/g68kJRMQ Southern Star Research will be contributing alongside a panel of industry peers from Sonic Clinical Trials, Prime Financial Group, Veritus Research, Accelagen Pty Ltd, Crux Biolabs #AustralianClinicalTrials #SaltLakeCity #Phoenix #Austrade #Biotech #ClinicalTrials
-
Daniel Evans reposted thisJoin me and Lloyd Prescott at American Society of Clinical Oncology (ASCO) 2026 Conference in Chicago, IL. Southern Star Research has extensive experience in Phase I - III Oncology trials across Australia, APAC, USA and Europe - learn more on how you can accelerate your timelines, achieve FPI sooner and save considerable costs in Australia whilst also leveraging the advantages that come with APAC clinical trials. #Oncology #ASCO2026 #SouthernStarResearch #ClinicalTrialsDaniel Evans reposted this𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐬 𝐭𝐚𝐤𝐞𝐬 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝐞𝐱𝐞𝐜𝐮𝐭𝐢𝐨𝐧. 𝐈𝐭 𝐭𝐚𝐤𝐞𝐬 𝐭𝐡𝐞 𝐫𝐢𝐠𝐡𝐭 𝐩𝐚𝐫𝐭𝐧𝐞𝐫. Southern Star Research will be attending 𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔 in Chicago from May 29 – June 2, 2026. Our CEO, Lloyd Prescott, and Director, Business Development, Daniel Evans will be onsite meeting biotech and medtech teams advancing oncology programs. At Southern Star Research, we support early-phase oncology trials with scientific insight, strong site relationships, and the speed advantages of Australia, with seamless expansion into APAC to enable multi-country studies without sacrificing speed or flexibility. If you are attending, we would be glad to connect. Book a meeting here: https://lnkd.in/gkABPivk #ASCO2026 #OncologyResearch #ClinicalTrials
-
Daniel Evans reposted thisDaniel Evans reposted thisAustrade North America | Australian Trade and Investment Commission invites you to participate in an upcoming seminar in #PhoenixAZ in association with Arizona BioIndustry Association (AZBio), City of Phoenix, and Phoenix Community and Economic Development. 📣 Exploring New Models of Global Clinical Trial Collaboration 🗓️ Thursday, June 18, 2026 ⏰ 12-2pm (MT) As #clinicaltrials become more complex and collaborative, these sessions will explore how Australia’s clinical trial ecosystem is structured, its key strengths and efficiencies, and present opportunities for #collaboration between USA and Australian stakeholders. Industry experts and local ecosystem partners will be on hand to network and provide practical insights to facilitate informed, capital-efficient decisions - irrespective of your current stage of development. Who should attend? 📌 Pharmaceutical & biotech R&D leaders 📌 Medical device companies 📌 Clinical operations and trial strategy decision-makers 📌 CROs and clinical service providers 📌 Academic, hospital, and research institution leaders 📌 Investors / VC with interest in Biotech / MedTech sectors 📌 Policy, innovation, and ecosystem stakeholders Register you interest below. Places are limited. ✒️ https://luma.com/nlp7adru Australian Trade and Investment Commission (Austrade) AusBiotech Medical Technology Association of Australia (MTAA) Medicines Australia ARCS Australia MTPConnect Joan Koerber-Walker Claudia Whitehead Phoenix Bioscience Core Venture Café Phoenix Sarah Waschler, CEM Accelagen Pty Ltd Greg Plunkett Crux Biolabs Stefan Cross Prime Financial Group George Zafiris MBA Sonic Clinical Trials Simon Dixon Pure Solutions Australia Catherine Osborne Southern Star Research Daniel Evans Veritus Research Cheryl-Ann Hawkins Kate Gunn NACD.DC, FAICD, ACHE Steve Potts Jacque Sokolov, MD University of Phoenix University of Arizona Arizona State UniversityAustralia: Exploring New Models of Global Clinical Trial Collaboration - Phoenix, AZ · LumaAustralia: Exploring New Models of Global Clinical Trial Collaboration - Phoenix, AZ · Luma
-
Daniel Evans reposted thisDaniel Evans reposted thisAustrade North America | Australian Trade and Investment Commission invites you to participate in an upcoming seminar in #PhoenixAZ in association with Arizona BioIndustry Association (AZBio), City of Phoenix, and Phoenix Community and Economic Development. 📣 Exploring New Models of Global Clinical Trial Collaboration 🗓️ Thursday, June 18, 2026 ⏰ 12-2pm (MT) As #clinicaltrials become more complex and collaborative, these sessions will explore how Australia’s clinical trial ecosystem is structured, its key strengths and efficiencies, and present opportunities for #collaboration between USA and Australian stakeholders. Industry experts and local ecosystem partners will be on hand to network and provide practical insights to facilitate informed, capital-efficient decisions - irrespective of your current stage of development. Who should attend? 📌 Pharmaceutical & biotech R&D leaders 📌 Medical device companies 📌 Clinical operations and trial strategy decision-makers 📌 CROs and clinical service providers 📌 Academic, hospital, and research institution leaders 📌 Investors / VC with interest in Biotech / MedTech sectors 📌 Policy, innovation, and ecosystem stakeholders Register you interest below. Places are limited. ✒️ https://luma.com/nlp7adru Australian Trade and Investment Commission (Austrade) AusBiotech Medical Technology Association of Australia (MTAA) Medicines Australia ARCS Australia MTPConnect Joan Koerber-Walker Claudia Whitehead Phoenix Bioscience Core Venture Café Phoenix Sarah Waschler, CEM Accelagen Pty Ltd Greg Plunkett Crux Biolabs Stefan Cross Prime Financial Group George Zafiris MBA Sonic Clinical Trials Simon Dixon Pure Solutions Australia Catherine Osborne Southern Star Research Daniel Evans Veritus Research Cheryl-Ann Hawkins Kate Gunn NACD.DC, FAICD, ACHE Steve Potts Jacque Sokolov, MD University of Phoenix University of Arizona Arizona State UniversityAustralia: Exploring New Models of Global Clinical Trial Collaboration - Phoenix, AZ · LumaAustralia: Exploring New Models of Global Clinical Trial Collaboration - Phoenix, AZ · Luma
-
Daniel Evans reposted thisDaniel Evans reposted thisAustrade North America | Australian Trade and Investment Commission invites you to participate in the upcoming seminar in #SaltLakeCity, in association with BioUtah, Economic Development Corporation of Utah (EDCUtah), and Salt Lake City Department of Economic Development. 📣 Exploring New Models of Global Clinical Trial Collaboration 🗓️ Wednesday, June 17, 2026 ⏰ 12-2pm (MT) As #clinicaltrials become more complex and collaborative, these sessions will explore how Australia’s clinical trial ecosystem is structured, its key strengths and efficiencies, and present opportunities for #collaboration between USA and Australian stakeholders. Industry experts and local ecosystem partners will be on hand to network and provide practical insights to facilitate informed, capital-efficient decisions - irrespective of your current stage of development. Who should attend? 📌 Pharmaceutical & biotech R&D leaders 📌 Medical device companies 📌 Clinical operations and trial strategy decision-makers 📌 CROs and clinical service providers 📌 Academic, hospital, and research institution leaders 📌 Investors / VC with interest in Biotech / MedTech sectors 📌 Policy, innovation, and ecosystem stakeholders Register you interest below. Places are limited. ✒️ https://luma.com/am7lzwxb Australian Trade and Investment Commission (Austrade) AusBiotech Medical Technology Association of Australia (MTAA) Medicines Australia ARCS Australia MTPConnect BioUtah Kelvyn Cullimore Denise Economic Development Corporation of Utah (EDCUtah) Rex Buys, MRED Erin Farr Salt Lake City Corporation Jake Maxwell Accelagen Pty Ltd Greg Plunkett Crux Biolabs Stefan Cross Prime Financial Group George Zafiris MBA Sonic Clinical Trials Simon Dixon Pure Solutions Australia Catherine Osborne Southern Star Research Daniel Evans Veritus Research Cheryl-Ann Hawkins BioHive BYU Andrew Robertson Paul Perreault Martin Jensen Jerry Henley David Bearss Ph.D. University of Utah
-
Daniel Evans reposted thisDaniel Evans reposted this𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐬 𝐭𝐚𝐤𝐞𝐬 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝐞𝐱𝐞𝐜𝐮𝐭𝐢𝐨𝐧. 𝐈𝐭 𝐭𝐚𝐤𝐞𝐬 𝐭𝐡𝐞 𝐫𝐢𝐠𝐡𝐭 𝐩𝐚𝐫𝐭𝐧𝐞𝐫. Southern Star Research will be attending 𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔 in Chicago from May 29 – June 2, 2026. Our CEO, Lloyd Prescott, and Director, Business Development, Daniel Evans will be onsite meeting biotech and medtech teams advancing oncology programs. At Southern Star Research, we support early-phase oncology trials with scientific insight, strong site relationships, and the speed advantages of Australia, with seamless expansion into APAC to enable multi-country studies without sacrificing speed or flexibility. If you are attending, we would be glad to connect. Book a meeting here: https://lnkd.in/gkABPivk #ASCO2026 #OncologyResearch #ClinicalTrials
-
Daniel Evans shared thisJoin me and Lloyd Prescott at American Society of Clinical Oncology (ASCO) 2026 Conference in Chicago, IL. Southern Star Research has extensive experience in Phase I - III Oncology trials across Australia, APAC, USA and Europe - learn more on how you can accelerate your timelines, achieve FPI sooner and save considerable costs in Australia whilst also leveraging the advantages that come with APAC clinical trials. #Oncology #ASCO2026 #SouthernStarResearch #ClinicalTrialsDaniel Evans shared this𝐀𝐝𝐯𝐚𝐧𝐜𝐢𝐧𝐠 𝐨𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐩𝐫𝐨𝐠𝐫𝐚𝐦𝐬 𝐭𝐚𝐤𝐞𝐬 𝐦𝐨𝐫𝐞 𝐭𝐡𝐚𝐧 𝐞𝐱𝐞𝐜𝐮𝐭𝐢𝐨𝐧. 𝐈𝐭 𝐭𝐚𝐤𝐞𝐬 𝐭𝐡𝐞 𝐫𝐢𝐠𝐡𝐭 𝐩𝐚𝐫𝐭𝐧𝐞𝐫. Southern Star Research will be attending 𝐀𝐒𝐂𝐎 𝟐𝟎𝟐𝟔 in Chicago from May 29 – June 2, 2026. Our CEO, Lloyd Prescott, and Director, Business Development, Daniel Evans will be onsite meeting biotech and medtech teams advancing oncology programs. At Southern Star Research, we support early-phase oncology trials with scientific insight, strong site relationships, and the speed advantages of Australia, with seamless expansion into APAC to enable multi-country studies without sacrificing speed or flexibility. If you are attending, we would be glad to connect. Book a meeting here: https://lnkd.in/gkABPivk #ASCO2026 #OncologyResearch #ClinicalTrials
-
Daniel Evans liked thisDaniel Evans liked thisBreaking through barriers to better care #IncannexHealthcare is developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. This #ClinicalTrialsDay we’re highlighting our available studies focused on advancing the development of our innovative therapeutics in the most effective and expedient manner possible. If you are a physician or patient interested in our investigational therapy #clinicaltrials, visit our site: https://lnkd.in/gpriNJYB
-
Daniel Evans liked thisDaniel Evans liked thisHappy Clinical Trials Day! Is your passion for clinical trials needing a new outlet? Is your background and expertise in early phase trials calling out for another challenge - like a soon to open phase I, 24 bed clinical trial unit on the Sunshine Coast? Our high performing team is looking for new talent to help establish our newest early phase facility. We have roles from entry to senior level. We can assist with relocation. We would love to hear from professionals with Phase I experience from around Australia, New Zealand, UK, Europe and US. Please get in touch llitewka@usc.edu.au +61429930449
-
Daniel Evans liked thisThank you to our amazing team!Daniel Evans liked thisBehind every potential breakthrough, is a reason why. This World Clinical Trials Day, we’re celebrating the impact of clinical research, and the people who make it happen. At Nucleus Network, we are proud to play a part in helping drive medical treatments forward through clinical research. Thank you to our participants and teams for helping move research forward - your passion and purpose help to advance medicine and improve lives. #WorldClinicalTrialsDay #ClinicalResearch #NucleusNetwork
-
Daniel Evans liked thisDaniel Evans liked thisTwo graduates, one proud dad. 🎓 Celebrating my son and daughter-in-law as they close this chapter at BYU and step into the "real world." Watching them earn their degrees side by side, one from the College of Life Sciences and one from the College of Computational, Mathematical, and Physical Sciences, has been such a joy. The future is bright for these two, and I couldn't be prouder. Go out and do good things, you two. 💙 #BYUGrad #ProudDad #Classof2026
-
Daniel Evans liked thisThis is a really great summary of Amplia's recent clinical trial announcements and of our work to date. Thanks Bulls N' Bears Amplia Therapeutics LimitedDaniel Evans liked thisAmplia Therapeutics Limited has launched a pivotal registration-enabling trial of #narmafotinib for #pancreaticcancer, testing better efficacy with daily dosing as it moves towards a potential FDA-approved Phase 3 study. $ATX #BULLSNBEARSWA Brisbane TimesAmplia takes aim at billion-dollar pancreatic cancer drug marketAmplia takes aim at billion-dollar pancreatic cancer drug market
-
Daniel Evans liked thisDaniel Evans liked thisBIG Pharma is staring down a major patent cliff with more than $300B in sales at risk in coming years. Just to put it into perspective: Nearly 200 drugs are going off-patent in the near future These include at least 69 blockbusters (>$1B in annual sales) This could lead to over 49% revenue decline for major companies Unlike the previous patent cliff, this one includes a fair number of biologics. A major shake-up is coming — and it will demand: Investment Innovation Strategy With this patent cliff, are we looking at the biggest losers or the biggest winners? Will this wave push pharma R&D towards new ways to strengthen and diversify portfolios? Source/Credit: Joanna Sadowska, PhD, EMBA hashtag #biopharmaceuticals hashtag #biotech hashtag #pharmaceuticals hashtag #pharma
-
Daniel Evans liked thisDaniel Evans liked thisMonopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease https://lnkd.in/gQrBkuicMonopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson DiseaseMonopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
-
Daniel Evans liked thisDaniel Evans liked thisOur CEO, Carol Curtis, Ph.D., and COO, Elaine H., will attend the 2026 BIO International Convention to provide updates on our therapeutic pipeline. This includes a remyelination approach for multiple sclerosis and a novel therapy to reduce endometriosis lesions. We look forward to engaging with industry leaders, partners, and investors to discuss our ongoing research on MS and endometriosis and to explore collaboration opportunities that drive innovation in these vital healthcare fields. #BIO2026 #BIOInternationalConvention #Biotech #DrugDevelopment #MultipleSclerosis #MSResearch #Endometriosis #WomensHealth #Neuroscience #CadenzaBio
-
Daniel Evans liked thisEdison Scientific dropped a new product AND a gigantic pharma deal today. This is the hustle we need in AIxScience!! 💪 Their new product, New Kosmos is amazing. In one of my first conversations with New Kosmos, ideas we came up with together ended up as patent claims less than two weeks later. The link to apply for early access is here: https:// https://lnkd.in/g95r9vDnDaniel Evans liked thisWe live in a golden age of biology. So why are people still dying from disease? Because discovery and development move slower than they should. Today, we’re partnering with Incyte to change that. Kosmos is now the first agent that can compress months of drug development into weeks, from the earliest stages of scientific discovery through to FDA approval. Incyte will be the first company to deploy it across their pipeline. Work that used to take a team of scientists months now happens in weeks. Patients can't wait, and neither can we.
Experience
Education
Recommendations received
10 people have recommended Daniel
Join now to viewView Daniel’s full profile
-
See who you know in common
-
Get introduced
-
Contact Daniel directly
Other similar profiles
Explore more posts
-
Asad Balal
Elixir Associates • 35K followers
Below are recent executive appointments from the past few days across the #Biotech, #CRO & #Pharma industry. 👨🔬 👩🔬 ➖ Altay Therapeutics Australia have appointed Jim Breitmeyer as their new CEO.✅ ➖ Kinaset Therapeutics have appointed Anesa Moyer as their new VP, Clinical Operations.✅ ➖ Autobahn Therapeutics, Inc. have appointed Jason Harris as their new CSO.✅ ➖ Ray Therapeutics, Inc. have appointed Michael Murtagh as their new CRO.✅ ➖ Soley Therapeutics have appointed Roya Nawabi as their new VP, Clinical Operations.✅ ➖ Tenvie Therapeutics have appointed Don O'Sullivan as their CBO.✅ ➖ Aquestive Therapeutics have appointed Matthew Greenhawt as their new CMO.✅ ➖ EyePoint have appointed Mike Campbell as their new CCO.✅ ➖ GenSight Biologics have appointed Fang Li, PhD RAC as their new CRO & CQO.✅ ➖ Caidya have appointed Michael Clay as their new COO.✅ ➖ Sana Biotechnology, Inc. have appointed Brian Piper as their new CFO.✅ ➖ CNS Pharmaceuticals, Inc. have appointed Dylan W. as their new CBO.✅ ➖ Galderma have appointed Luigi La Corte as their new CFO.✅ ➖ Longeveron have appointed Steve Willard as their new CEO.✅ ➖ Artios have appointed Caryn Barnett as their new VP, Clinical Operations.✅ Huge congratulations to all these incredible leaders from myself & everyone at Elixir Associates. 👏 👏 👏 #Appointments #Leaders #Executive #Elixir #Leadership #Hiring #News #DrugDevelopment #Pharma #LifeSceinces #Biotech #Bio #Therapeutics #Staffing #Recruitment #ClinicalDevelopment #ClinicalResearch #Science
25
-
Daniel Nation
SJLife Sciences • 20K followers
𝐒𝐂𝐄 | 𝐓𝐡𝐞 𝐒𝐞𝐜𝐫𝐞𝐭 𝐖𝐞𝐚𝐩𝐨𝐧 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐏𝐡𝐚𝐫𝐦𝐚 & 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 💻 𝘞𝘩𝘺 𝘵𝘩𝘦 𝘚𝘵𝘢𝘵𝘪𝘴𝘵𝘪𝘤𝘢𝘭 𝘊𝘰𝘮𝘱𝘶𝘵𝘪𝘯𝘨 𝘌𝘯𝘷𝘪𝘳𝘰𝘯𝘮𝘦𝘯𝘵 (𝘚𝘊𝘌) 𝘐𝘴 𝘉𝘦𝘤𝘰𝘮𝘪𝘯𝘨 𝘢 𝘚𝘵𝘳𝘢𝘵𝘦𝘨𝘪𝘤 𝘈𝘴𝘴𝘦𝘵! 𝐅𝐫𝐨𝐦 𝐓𝐞𝐜𝐡𝐧𝐢𝐜𝐚𝐥 𝐓𝐨𝐨𝐥 𝐭𝐨 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐃𝐢𝐟𝐟𝐞𝐫𝐞𝐧𝐭𝐢𝐚𝐭𝐨𝐫 In today’s fast-paced clinical development environment, the SCE has evolved from a back-office necessity to a key competitive advantage. Modern pharma and biotech teams aren’t just running stats — they need platforms that deliver: 🔹 End-to-end traceability from data ingestion to regulatory-ready outputs 🔹 Scalable, cloud-native computation for genomics, RWD, imaging, and complex trials 🔹 Robust validation and compliance frameworks (GxP, global regulations) 🔹 Seamless collaboration across statisticians, data scientists, and cross-functional teams 🔹 Automation and reproducibility to reduce bottlenecks under tight timelines 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐋𝐞𝐚𝐝𝐞𝐫𝐬 Several organizations are making major investments to modernize their SCE and analytics infrastructure: AstraZeneca | Leveraging multiple cloud platforms for genomics and bioinformatics, enabling rapid, high-throughput analytics. Eli Lilly and Company | Partnered with NVIDIA to build a supercomputer, signaling the move toward AI/ML-enabled, compute-heavy drug development. IQVIA | Combining cloud-based analytics and data management to offer scalable, regulated SCE services to biotech and pharma globally. Clinical-data analytics providers | Instem, Oracle, Medidata Solutions, Veeva Systems, and SAS are scaling up cloud-based clinical-trial and real-world-data platforms that underpin SCE - like functionality (data integration, analytics, regulatory compliance, trial management 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬 A modern SCE isn’t just a computation engine — it’s a cornerstone of speed, quality, and trust. When implemented well, it enables: ✅ Clean, auditable, submission-ready outputs ✅ Reproducible and collaborative analytics workflows ✅ Faster insights from complex pipelines (genomics, imaging, AI/ML modeling, adaptive trials) 𝐓𝐡𝐞 𝐁𝐨𝐭𝐭𝐨𝐦 𝐋𝐢𝐧𝐞 Investing in a robust, scalable, and compliant SCE positions organizations to win in operational efficiency, R&D agility, and long-term competitiveness. 💬 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐭𝐲 𝐐𝐮𝐞𝐬𝐭𝐢𝐨𝐧: How is your organization evolving its SCE? What challenges or gains have you seen?
9
1 Comment -
Roby Zomer
Bot 4 Future • 3K followers
“This transaction brings together clinically validated IP, EU commercial infrastructure, and manufacturing scale under one platform. We are building a capital-efficient engine to deliver next-generation formulations of CannEpil® and CimetrA® – at scale, with speed, and with enduring IP protection. It positions Argent to expand globally while strengthening our core pipeline.”
7
1 Comment -
Proactive
27K followers
Inside Biotech: Trial tweaks, TGA clearance and US site openings headline busy day for biotechs: A cluster of attention-grabbing announcements from ASX-listed biotech juniors this morning touched on several key pressure points for the sector — clinical timelines, regulatory clearance, scientific credibility and US trial execution. Updates from Racura Oncology, Memphasys, Noxopharm and Amplia Therapeutics cover noteworthy advancements including trial protocol amendments designed to pull forward key data, Australian regulatory clearance for a key product, high-impact scientific publication and the expansion of US trial sites in pancreatic cancer. The session underscores the steady flow of operational and regulatory milestones shaping the ASX biotech landscape this year, from early mechanistic validation to commercial rollouts and international trial expansion. Here’s a closer look at the details. Racura adds new blood test to CPACS trial Racura Oncology Ltd (ASX:RAC, FRA:FN3) announced that it has amended its RAC-010 cardioprotection and anticancer synergy (CPACS)... http://dlvr.it/TRBH8G
-
Kalkine Media Australia
9K followers
Actinogen’s ASX move signals fresh momentum for local biotech — as strategic developments and market activity highlight growing investor interest in Australia’s biotech landscape. 🧬📈 https://zurl.co/wEDq3 #Actinogen #BiotechMomentum
-
Central Pharmacy Logistics Australia
4K followers
At Central Pharmacy Logistics Australia, we are proud to support the evolution of decentralised clinical trials by offering on-site manufacturing and compounding of investigational medicinal products (IMPs). This integrated approach reduces logistical complexity, shortens timelines, and ensures that therapies are delivered efficiently, safely, and in full compliance with regulatory requirements - whether to a clinical site or directly to the patient. By aligning manufacturing capabilities with trial operations, we enable a more agile, responsive, and patient-focussed model of research. If you are looking for a trusted partner to accelerate the development and manufacturing of your next innovative trial therapeutic, we would love to connect and explore how we can support your needs and goals. #drugdevelopment #drugmanufacturing #manufacturing #compounding #decentralisedclinicaltrials #clinicaltrials #clinicalresearch #pharmacy #logistics
39
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Daniel Evans in Australia
-
Daniel Evans
Greater Brisbane Area -
Daniel Evans
Mckellar -
Daniel Evans
Sydney, NSW -
Daniel Evans
Brisbane, QLD -
Daniel Evans
Sydney, NSW
147 others named Daniel Evans in Australia are on LinkedIn
See others named Daniel Evans